Targeting the K-Ras/PDEδ Protein–Protein Interaction: The Solution for Ras-Driven Cancers or Just Another Therapeutic Mirage?

Authors

  • Brendan Frett,

    1. Department of Pharmacology & Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721 (USA)
    2. BIO5 Oro Valley (BIO5OV), University of Arizona, 1580 E. Hanley Blvd, Oro Valley, AZ 85737 (USA)
    Search for more papers by this author
  • Dr. Yuanxiang Wang,

    1. Department of Pharmacology & Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721 (USA)
    2. BIO5 Oro Valley (BIO5OV), University of Arizona, 1580 E. Hanley Blvd, Oro Valley, AZ 85737 (USA)
    Search for more papers by this author
  • Prof. Dr. Hong-yu Li

    Corresponding author
    1. Department of Pharmacology & Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721 (USA)
    2. BIO5 Oro Valley (BIO5OV), University of Arizona, 1580 E. Hanley Blvd, Oro Valley, AZ 85737 (USA)
    • Department of Pharmacology & Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721 (USA)
    Search for more papers by this author

Abstract

original image

The holy grail, finally? After years of unsuccessful attempts at drugging the Ras oncogene, a recent paper by Zimmerman et al. has revealed the possibility of inhibiting Ras signaling on a clinically relevant level by blocking the K-Ras/PDEδ protein–protein interaction. The results, reported in Nature, are highlighted herein with future implications and directions to evaluate the full clinical potential of this research.

Ancillary